Epic Sciences

In September 2018, Epic Sciences announced a $52 million Series C financing in which Deerfield participated. The Company is developing novel diagnostics to personalize and advance the treatment and management of cancer. Epic Sciences’ mission is to enable the rapid and non-invasive detection of genetic and molecular changes in cancer throughout a patient’s journey.